- Previous Close
24.62 - Open
25.01 - Bid 26.33 x 200
- Ask 26.40 x 400
- Day's Range
25.01 - 26.42 - 52 Week Range
13.48 - 31.22 - Volume
705,851 - Avg. Volume
638,932 - Market Cap (intraday)
2.626B - Beta (5Y Monthly) 1.07
- PE Ratio (TTM)
-- - EPS (TTM)
-3.10 - Earnings Date Nov 5, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
49.54
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.
www.zailaboratory.comRecent News: ZLAB
View MorePerformance Overview: ZLAB
Trailing total returns as of 10/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZLAB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZLAB
View MoreValuation Measures
Market Cap
2.58B
Enterprise Value
2.04B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.94
Price/Book (mrq)
3.73
Enterprise Value/Revenue
6.32
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-92.44%
Return on Assets (ttm)
-21.13%
Return on Equity (ttm)
-36.46%
Revenue (ttm)
322.71M
Net Income Avi to Common (ttm)
-298.33M
Diluted EPS (ttm)
-3.10
Balance Sheet and Cash Flow
Total Cash (mrq)
630.05M
Total Debt/Equity (mrq)
11.88%
Levered Free Cash Flow (ttm)
-193.33M
Research Analysis: ZLAB
View MoreCompany Insights: ZLAB
ZLAB does not have Company Insights